Fast-acting fentanyl preparations and pain management

QJM: An International Journal of Medicine

Volumn 106, Issue 10, 2013, Pages 887-890

  McWilliams, K ^a   Fallon, M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARCHIMEDES; CEPHALON; FENTANYL; FENTANYL CITRATE; MORPHINE; OPIATE; PROSTRAKAN; TAKEDA; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL TRIAL; CONSENSUS; DRUG ACCUMULATION; DRUG DEPENDENCE; DRUG DOSE TITRATION; DYSPNEA; HUMAN; MEDICAL SPECIALIST; NAUSEA; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT INDICATION; VOMITING;

ANALGESICS, OPIOID; BREAKTHROUGH PAIN; DRUG DOSAGE CALCULATIONS; FENTANYL; HUMANS; NEOPLASMS; PAIN MANAGEMENT;

EID: 84884708121     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hct092     Document Type: Article

References (23)

1. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999; 82:263-74.
2. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59:850-6.
3. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009; 13:331-8.
4. Breivik H, Cherny N, Collett B, de Conno F, Filbert M, Foubert AJ, et al. Cancer related pain: a pan-European survey of prevalence, treatment and patient attitudes. Ann Oncol 2009; 20:1420-33.
5. Laird BJA, Walley J, Murray GD, Clausen E, Colvin LA, Fallon MT. Characterisation of cancer-induced bone pain: an exploratory study. Support Cancer Care 2011; 19:1393-401.
6. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41:273-81.
7. Zeppetella G. Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care 2009; 18:331-7.
8. Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. Pharm Ther 2005; 30:354-61.
9. Streisand J, Busch MA, Egan TD, Smith BG, Gay M, Pace NL. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anaesthesiology 1999; 88:305-9.
10. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, et al. Breakthrough cancer pain: a randomized controlled trial comparing oral transmucosal fentanyl citrate and morphine sulfate immediate release. Pain 2001; 91:123-30.
11. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomised, double-blind, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998; 90:611-6.
12. Portenoy RK. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006; 22:805-11.
13. Slatkin NE, Xie F,Messina J, Segal TJ. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant patients with cancer related chronic pain. J Support Oncol 2007; 5:327-34.
14. Rauck RL. Efficacy and long-tern tolerability of sublingual fentanyl for orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opinion 2009; 25:2877-85.
15. Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 micrograms for breakthrough pain in patients with cancer: a phase III multinational randomised, doubleblind placebo-controlled, crossover trial with a 10 month, open label extension treatment period. Clin Ther 2009; 6:1117-91.
16. Mercadante S, Radbruch L, Davies A, Poulin P, Sitte T, Perkins P, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain-an open label, randomised, crossover trial. Curr Med Res Opin 2009; 25:2805-15.
17. Portenoy RK, Burton AW, Gabrail N, Taylor D. A multi-centre, double-blind, multi-crossover study of fentanyl pectin nasal spray in the treatment of breakthrough cancer pain. Pain 2010; 151:617-24.
18. Fallon MT, Reale C, Dvies A, Eberhard L, Kumar K, Stachowiak A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, doubledummy multiple-crossover study. J Support Oncol 2010; 9:224-31.
19. Jandhyala R. Various formulation of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. Support Palliat Care 2012; 2:156-62.
20. Taylor DR. Impact of breakthrough cancer pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate. Pain Med 2007; 8:281-8.
21. Gauna AA. Oral transmucosal fentanyl citrate for dyspnoea in terminally ill patients: an observational case series. J Palliat Med 2008; 11:643-8.
22. Benitez-Rosario MA, Martin AS, Feria M. Oral transmucosal fentanyl citrate in the management of dyspnoea crises in cancer patients. JPSM 2005; 30:395-7.
23. Nunez-Olarte JM, Alvarez-Jiminez P. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain. JPSM 2011; 42:e6-8.